Posted by Michael Wonder on 01 Sep 2020
New formulation of Entyvio is included in the high-cost protection with limitation
1 September 2020 - Entyvio (vedolizumab) in the new dosage form of a solution for subcutaneous injection is included in the high-cost protection with restriction as of 28 August 2020.
Entyvio is used in the inflammatory bowel diseases ulcerative colitis and Crohn's disease.
TLV assessed that Entyvio in the already subsidised dosage form is a relevant comparison alternative to Entyvio solution for injection and that the new dosage form has a comparable effect as the already subsidised dosage form.
